How to Get AndroGel in Virginia

Virginia Allows Telehealth Prescribing of AndroGel

Virginia law permits telehealth prescribing of Schedule III controlled substances, including testosterone gel, provided the prescriber establishes a bona fide patient-provider relationship. The Virginia Board of Medicine updated its telemedicine guidelines in 2024, confirming that synchronous audio-video encounters satisfy this requirement for controlled substance initiation.

This means a Virginia resident does not need to visit a brick-and-mortar clinic to start testosterone replacement therapy (TRT). Platforms operating under Virginia licensure can evaluate symptoms, order labs, and transmit an electronic prescription to any licensed pharmacy in the state. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism and unequivocally low serum testosterone, defined as total testosterone below 300 ng/dL on at least two morning samples.

A telehealth visit typically lasts 15 to 25 minutes. The provider will review your symptoms (fatigue, reduced libido, depressed mood, decreased lean mass), lab results, and medical history before determining whether AndroGel is appropriate. If you have a history of polycythemia, untreated obstructive sleep apnea, or prostate cancer, testosterone therapy may be contraindicated. The FDA-approved prescribing information for AndroGel lists these contraindications explicitly.

Virginia does not require an initial in-person visit before a telehealth provider can prescribe a Schedule III medication. This removes a significant barrier for patients in rural parts of the state, where endocrinologists or urologists may be over an hour away.

Lab Requirements Before Starting AndroGel in Virginia

Every prescriber, whether in-person or via telehealth, must confirm biochemical hypogonadism before writing a testosterone prescription. The diagnostic standard requires two separate morning total testosterone measurements drawn between 7:00 a.m. and 10:00 a.m., when levels peak in the diurnal cycle.

The Endocrine Society guideline specifies a threshold of total testosterone below 300 ng/dL (10.4 nmol/L) measured by a reliable assay. Some providers also check free testosterone and sex hormone-binding globulin (SHBG) to clarify borderline cases. For men with obesity, SHBG tends to run low, which can make total testosterone appear misleadingly reduced while free testosterone remains normal.

Beyond testosterone levels, a complete pre-treatment workup includes:

• Complete blood count (CBC): Baseline hematocrit is essential because testosterone therapy increases erythropoiesis. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older, found that testosterone gel raised hematocrit by an average of 2.6 percentage points over 12 months. A hematocrit above 50% before treatment is a relative contraindication.
• Lipid panel: Testosterone may modestly reduce HDL cholesterol. Baseline lipids help track cardiovascular risk over time.
• PSA (men over 40): Prostate-specific antigen screening before and during therapy follows AUA/Endocrine Society recommendations. A PSA above 4.0 ng/mL warrants urology referral before initiating testosterone.
• Hepatic function panel: While testosterone gel has minimal first-pass hepatic metabolism compared to oral formulations, liver function at baseline establishes a reference point.

Virginia Quest Diagnostics and Labcorp locations accept standing orders from telehealth providers. Most telehealth platforms generate a lab requisition within 24 hours of enrollment, and results return in 2 to 4 business days.

Who Can Prescribe AndroGel in Virginia: MD, NP, and PA Scope

Virginia grants prescriptive authority for Schedule III controlled substances to physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA), each with specific regulatory requirements.

Physicians hold independent prescriptive authority. An NP in Virginia gained full practice authority under Virginia Code § 54.1-2957 after completing a supervised practice period, which was reduced from five years to two years effective 2022. After meeting this requirement, NPs can independently prescribe testosterone gel without physician oversight. PAs prescribe under a practice agreement with a supervising physician, which must include authorization for Schedule III substances.

From a clinical standpoint, the prescriber's specialty matters less than their familiarity with male hypogonadism management. Endocrinologists, urologists, and men's health specialists see the highest volumes of TRT patients, but primary care providers, including NPs and PAs in family medicine, prescribe testosterone regularly. The Endocrine Society guideline does not restrict TRT initiation to any single specialty.

If your current provider is reluctant to prescribe, a second opinion through telehealth is a practical path. Virginia's telehealth framework means you are not limited to providers in your immediate geographic area, only to those licensed in the state.

Virginia Medicaid and Commercial Insurance Coverage

Virginia Medicaid covers AndroGel for the FDA-approved indication of male hypogonadism, but requires prior authorization (PA). The PA process verifies that the patient has documented biochemical and clinical hypogonadism, has no absolute contraindications, and has tried (or has a reason to bypass) generic testosterone formulations first.

For commercial insurance, coverage patterns follow national trends. Most major carriers in Virginia, including Anthem Blue Cross Blue Shield, Aetna, and Cigna, cover generic testosterone gel 1.62% at a Tier 2 or Tier 3 copay. Brand-name AndroGel often sits at Tier 3 or requires a step-through from generic topical testosterone.

The average out-of-pocket cost varies widely:

• Generic testosterone gel 1.62% with insurance: $30 to $75 per month
• Brand AndroGel 1.62% with insurance (Tier 3): $75 to $150 per month
• Brand AndroGel without insurance: approximately $500 to $700 per month at retail pharmacies
• 503A compounded testosterone cream/gel: $40 to $100 per month, depending on the pharmacy

A GoodRx or manufacturer copay card can reduce brand AndroGel costs for commercially insured patients. AbbVie has historically offered copay assistance programs that cap monthly out-of-pocket expenses at $30 to $50 for eligible patients.

For Virginia Medicaid recipients, the prior authorization form typically requires the prescriber to submit the two qualifying testosterone values, a statement of symptoms, and documentation that the patient has no contraindications listed in the FDA label. Approval turnaround ranges from 24 hours to 5 business days.

Prior Authorization Requirements and Documentation

Prior authorization for AndroGel in Virginia, whether through Medicaid or commercial insurance, follows a predictable documentation pattern. Understanding what the insurer needs before the request is submitted can prevent delays and denials.

Standard PA documentation includes:

1. Two morning serum total testosterone values below 300 ng/dL, drawn on separate days. Lab reports must include the collection time, reference range, and assay method.
2. ICD-10 diagnosis code: E29.1 (testicular hypofunction) is the most commonly accepted code for male hypogonadism.
3. Clinical symptoms: The prescriber's note should document at least two signs or symptoms consistent with testosterone deficiency (reduced libido, erectile dysfunction, fatigue, depressed mood, decreased muscle mass, increased body fat, or reduced bone mineral density).
4. Contraindication screening: Documentation that the patient does not have breast or prostate cancer, hematocrit above 54%, untreated severe obstructive sleep apnea, uncontrolled heart failure, or a desire for near-term fertility.
5. Step therapy justification (if required): Some commercial plans require a trial of generic testosterone gel or testosterone cypionate injection before approving brand AndroGel. If the patient has a clinical reason to avoid injections (needle phobia, anticoagulant therapy, or preference for steady-state pharmacokinetics), the prescriber documents this as medical necessity.

The Endocrine Society clinical practice guideline serves as the primary reference standard that insurers use to evaluate PA requests. Citing this guideline in the PA submission strengthens the case.

Denials can be appealed. Virginia insurance regulations require carriers to process internal appeals within 30 days for non-urgent requests. For Medicaid, the Department of Medical Assistance Services (DMAS) handles appeals through an administrative hearing process.

503A Compounding Pharmacies in Virginia

Virginia licenses 503A compounding pharmacies under the Virginia Board of Pharmacy, and these facilities can legally prepare and dispense compounded testosterone gel or cream with a valid patient-specific prescription. Unlike 503B outsourcing facilities, 503A pharmacies compound in response to individual prescriptions rather than in bulk.

Compounded testosterone formulations are not FDA-approved and do not carry the same bioequivalence data as brand AndroGel. The FDA's guidance on compounding distinguishes between commercially available products and compounded alternatives. Prescribers may order compounded testosterone when the patient needs a dose strength, base vehicle, or combination not available in a manufactured product, or when cost is a barrier.

In practice, many Virginia 503A pharmacies compound testosterone cream in concentrations ranging from 50 mg/mL to 200 mg/mL. Prices typically fall between $40 and $100 per month, significantly less than brand AndroGel at retail price. Some Virginia compounding pharmacies ship within state borders, making them accessible to patients in rural areas without a nearby compounding facility.

A compounded testosterone prescription still requires the same diagnostic workup and follow-up monitoring as brand AndroGel. The active hormone is identical. The differences lie in the vehicle (cream vs. gel), the excipient profile, and the absence of FDA-mandated bioavailability testing. A 2017 analysis in the Journal of Clinical Endocrinology and Metabolism found that compounded testosterone formulations produced variable serum levels compared to FDA-approved products, reinforcing the need for follow-up labs 4 to 6 weeks after starting treatment.

Timeline: From First Consultation to First Dose

The total elapsed time from scheduling a consultation to applying your first dose of AndroGel in Virginia depends on whether you already have qualifying lab work.

If you have recent labs (within 6 months) showing two low testosterone values:

• Telehealth consultation: scheduled within 1 to 3 days
• Prescription transmitted: same day as consultation
• Pharmacy fill (no PA required): 1 to 2 days
• Total: 2 to 5 days

If you need new labs:

• Lab requisition issued: 1 day after enrollment
• Blood draw and results: 2 to 5 days
• Second draw (required on a separate day): add 2 to 5 days
• Telehealth consultation after results: 1 to 3 days
• Prescription and fill: 1 to 3 days
• Total: 7 to 16 days

If prior authorization is needed:

• Add 1 to 5 business days for PA processing
• Add 2 to 10 business days if an appeal is required after initial denial

The fastest path is to have qualifying lab work already in hand when you schedule your first visit. If you have had testosterone tested by your PCP in the past 6 months and levels were below 300 ng/dL on two occasions, bring those results to your telehealth appointment.

Monitoring and Follow-Up After Starting AndroGel

Starting testosterone gel is not a one-time event. The Endocrine Society guideline recommends follow-up labs at 3 months, 6 months, and then annually. The T-Trials confirmed that testosterone gel produced consistent physiological levels in older men over 12 months, but individual responses vary based on application site, body composition, and adherence.

Follow-up labs should include:

• Total testosterone level (drawn 2 to 8 hours after gel application): Target range is 400 to 700 ng/dL for most men on TRT
• Hematocrit: If it exceeds 54%, the dose should be reduced or therapy paused. The T-Trials reported that 5.5% of men on testosterone gel experienced hematocrit above 54% versus 2.0% on placebo.
• PSA: A rise greater than 1.4 ng/mL over 12 months, or an absolute value above 4.0 ng/mL, triggers a urology referral per the AUA screening guidelines
• Lipid panel: Recheck at 6 to 12 months

Virginia telehealth platforms that prescribe AndroGel should be coordinating these follow-up labs as part of ongoing care. If your provider is not ordering follow-up bloodwork, that is a red flag. Testosterone therapy requires monitoring, and the standard of care in Virginia is no different from any other state.

Dose adjustments are common. The standard starting dose of AndroGel 1.62% is 40.5 mg applied once daily. Based on serum levels at the 3-month mark, your provider may titrate up to 81 mg daily or down to 20.25 mg daily. The goal is a trough testosterone in the mid-normal range without pushing hematocrit above safe limits.

Transferring a Testosterone Prescription to Virginia

If you are moving to Virginia from another state and already have an active AndroGel prescription, you can transfer it to a Virginia pharmacy. The process requires that the prescribing provider holds an active DEA registration and that the receiving Virginia pharmacy can verify the prescription's validity.

For Schedule III substances, Virginia pharmacies can accept prescription transfers electronically or by phone. The originating pharmacy contacts the Virginia pharmacy directly, and the transfer is logged in both systems. No new prescription is needed for the remaining refills. Once refills are exhausted, you will need to establish care with a Virginia-licensed provider to continue therapy.

If your previous provider is not licensed in Virginia, they cannot write new prescriptions for you in this state. A telehealth platform licensed in Virginia can review your medical records, confirm your diagnosis, and continue your therapy without requiring you to repeat the full diagnostic workup from scratch, provided your existing records include two qualifying testosterone levels and recent monitoring labs.